Results 201 to 210 of about 7,293,032 (313)
ABSTRACT Extracellular vesicles (EVs) are nanoscale membrane‐bound structures that play a pivotal role in intercellular communication by transporting bioactive molecules, including proteins, lipids, nucleic acids, and organelles, between cells. Originating from the endosomal pathway, EVs reflect the physiological and pathological status of their parent
Emine İncilay Torunoğlu +3 more
wiley +1 more source
Fibrin Clot Properties in Aneurysmal Coronary Artery Disease: CARE-ANEURYSM Study. [PDF]
Chmiel J +10 more
europepmc +1 more source
ABSTRACT Cell‐based models are highly valuable platforms for preclinical studies of atherosclerosis, offering controllable environments to investigate disease mechanisms. Three‐dimensional (3D) spheroids, a class of cell‐based models, enable the study of atherosclerotic disease phenomena under physiologically relevant yet controlled conditions. In this
Ibukunoluwa Naiyeju +2 more
wiley +1 more source
Triglyceride-glucose index is associated with the severity of coronary artery disease. [PDF]
Wang D +9 more
europepmc +1 more source
LSPR biosensing enables rapid, sensitive, and low‐sample‐volume detection of biomarkers, with broad applications in diagnosing cancer, infectious, and chronic diseases. Advances in nanostructure design, micro/nanofabrication, and microfluidic integration have expanded the potential of LSPR sensors in biomedical diagnostics.
Zhaoxin Geng +4 more
wiley +1 more source
NP‐SF, designed to target macrophage Dectin‐1 and activated platelets, selectively accumulated in ischemic myocardium, where it was taken up by macrophages after platelet hitchhiking. By inhibiting NLRC5‐related PANoptosis, NP‐SF significantly attenuated pathological damage, and effectively preserved cardiac function in a murine ischemia–reperfusion ...
Guanye Yu +13 more
wiley +1 more source
Colchicine in Coronary Artery Disease-Too Much of a Good Thing? [PDF]
Lo HZ, Patel S, Layland J.
europepmc +1 more source
ABSTRACT Background Biodegradable‐polymer (BP) drug‐eluting stents (DES) were developed to mitigate potential late adverse events related to persistent durable polymers in durable‐polymer (DP) DES; however, contemporary long‐term real‐world comparative data remain limited. Aims We aimed to compare the 5‐year clinical outcomes of contemporary BP‐DES and
Yangyoun Lee +6 more
wiley +1 more source

